Cardinal health predicts 2022 to be turning point for biosimilars in the u.s.

Dublin, ohio , feb. 7, 2022 /prnewswire/ -- today cardinal health published its 2022 biosimilars report: the u.s. journey and path ahead, a publication that brings together the latest industry data on biosimilar utilization and payer coverage with survey data from healthcare providers, and views from leading physicians and experts on biosimilars. the report delivers robust data and insights on where biosimilar adoption stands today in the u.s. and what is expected in 2022 and beyond as biosimilars come to market in key disease categories such as diabetes and immunology.
CAH Ratings Summary
CAH Quant Ranking